321 filings
Page 3 of 17
6-K
sj5ny3b1 07jxgaa1wxd
11 May 22
BELLUS Health Reports First Quarter 2022 Financial Results and Business Highlights
5:23pm
6-K
njs7r0qo he50as94
11 May 22
Condensed Consolidated Interim Financial Statements of
5:05pm
6-K
9z4k9a8k 09jmgjk02a
2 May 22
BELLUS Health to Present Late-Breaking Clinical Data from the Phase 2b SOOTHE Trial of BLU-5937 at the ATS 2022 International Conference
7:00am
6-K
5jw po5us
25 Apr 22
BELLUS Health to Participate in Multiple Upcoming Investor Conferences
4:02pm
6-K
n0b2 vpt20ww3
7 Apr 22
Notice of Annual Meeting of Shareholders
9:01am
6-K
6i9 k8b4ay2x
5 Apr 22
Current report (foreign)
4:07pm
6-K
sj8wt06u4zmfn pv
4 Mar 22
Report of Foreign Private Issuer for the Month of March 2022
11:32am
6-K
w5r4w0 9j
1 Mar 22
BELLUS Health to Participate in the Cowen & Co. 42nd Annual Health Care Conference
7:00am
6-K
4o1lxy6
23 Feb 22
BELLUS Health Reports Year 2021 Financial Results and Business Highlights
4:01pm
6-K
9c2s2p
17 Dec 21
BELLUS Health Closes US$200 Million Public Offering of Common Shares in Canada and the United States
4:03pm
6-K
lfj9ky4x5p 4rjyj
15 Dec 21
BELLUS Health Announces Pricing of US$200 Million Public Offering in Canada and the United States
5:15pm
6-K
qb6 8ejdm0946ue
13 Dec 21
BELLUS Health Announces the Launch of a Public Offering of Common Shares in Canada and the United States
4:07pm
6-K
djw1r
13 Dec 21
BELLUS Health Announces Positive Topline Results from its Phase 2b SOOTHE Trial of BLU-5937 for the Treatment of Refractory Chronic Cough
7:19am
6-K
hra1wdyauyn7cog6
13 Dec 21
BELLUS Health Announces Positive Topline Results from its Phase 2b SOOTHE Trial of BLU-5937 for the Treatment of Refractory Chronic Cough
7:00am
6-K
h0495 qlvrms
10 Nov 21
Condensed Consolidated Interim Financial Statements of
4:42pm
6-K
dss pjehjx75f9yixqp
10 Nov 21
BELLUS Health Reports Third Quarter 2021 Financial Results and Business Highlights
4:30pm
6-K
2zlw4rvq
10 Nov 21
BELLUS Health to Participate in Two Upcoming Healthcare Investor Conferences
7:00am
6-K
7jyqbkl3mr9olb
1 Nov 21
Bellus Health Inc. 6-K
7:00am
6-K
qa8muk
23 Sep 21
Topline results from both studies are expected in December 2021
7:00am
6-K
kmes65j s1
13 Sep 21
BELLUS Health Announces Positive Interim Analysis from the Phase 2b SOOTHE Trial of BLU-5937 in Refractory Chronic Cough
7:45am